Sionna Therapeutics, Inc. Common Stock SION Balance Sheet Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $59.41M+53.3% | $38.75M-1.9% | ||
| $241.42M+59.9% | $150.99M— | ||
| $2.23M-9.8% | $2.47M— | ||
| $74.42M+263% | $20.51M— | ||
| $325.95M+75.5% | $185.75M— | ||
| $8.18M— | —— | ||
| $11.71M+12.4% | $10.42M— | ||
| $19.12M+0.1% | $19.1M— | ||
| 500M+9,999,900% | 5K— | ||
| -$256.35M-41.6% | -$181.09M— | ||
| $306.83M+287% | -$163.71M-42.5% | ||
| $325.95M+75.5% | $185.75M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Sionna Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 22.60 — current assets exceed current liabilities.
- Where does Sionna Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.